AU738592C - Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase - Google Patents

Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase

Info

Publication number
AU738592C
AU738592C AU36175/97A AU3617597A AU738592C AU 738592 C AU738592 C AU 738592C AU 36175/97 A AU36175/97 A AU 36175/97A AU 3617597 A AU3617597 A AU 3617597A AU 738592 C AU738592 C AU 738592C
Authority
AU
Australia
Prior art keywords
cells
oligonucleotide
antisense
ribonucleotide reductase
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36175/97A
Other languages
English (en)
Other versions
AU3617597A (en
AU738592B2 (en
Inventor
Jim A. Wright
Aiping H. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptose Biosciences Inc
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Publication of AU3617597A publication Critical patent/AU3617597A/en
Publication of AU738592B2 publication Critical patent/AU738592B2/en
Application granted granted Critical
Publication of AU738592C publication Critical patent/AU738592C/en
Assigned to LORUS THERAPEUTICS INC. reassignment LORUS THERAPEUTICS INC. Alteration of Name(s) in Register under S187 Assignors: GENESENSE TECHNOLOGIES, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU36175/97A 1996-08-02 1997-08-01 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase Ceased AU738592C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2304096P 1996-08-02 1996-08-02
US60/023040 1996-08-02
US3995997P 1997-03-07 1997-03-07
US60/039959 1997-03-07
PCT/CA1997/000540 WO1998005769A2 (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU97321/01A Division AU9732101A (en) 1996-08-02 2001-12-19 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase

Publications (3)

Publication Number Publication Date
AU3617597A AU3617597A (en) 1998-02-25
AU738592B2 AU738592B2 (en) 2001-09-20
AU738592C true AU738592C (en) 2002-07-25

Family

ID=26696655

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36175/97A Ceased AU738592C (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase

Country Status (12)

Country Link
US (1) US5998383A (enExample)
EP (1) EP0917569B1 (enExample)
JP (1) JP4301576B2 (enExample)
CN (1) CN1189562C (enExample)
AT (1) ATE309345T1 (enExample)
AU (1) AU738592C (enExample)
CA (1) CA2262776C (enExample)
DE (1) DE69734589T2 (enExample)
ES (1) ES2256893T3 (enExample)
IL (2) IL128124A0 (enExample)
NZ (1) NZ333802A (enExample)
WO (1) WO1998005769A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
EP0954574A2 (en) * 1996-07-01 1999-11-10 Jim A. Wright Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
US6593305B1 (en) 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
WO1998041231A1 (en) * 1997-03-19 1998-09-24 Genesense Technologies, Inc. Suppression of malignancy utilizing ribonucleotide reductase r1
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ES2374534T3 (es) * 1998-03-20 2012-02-17 Commonwealth Scientific And Industrial Research Organisation Control de la expresión de genes.
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6642033B1 (en) * 1999-07-20 2003-11-04 V.I. Technologies, Inc. Nucleic acids for detecting parvovirus and methods of using same
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CN1301816A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
CN1426466A (zh) * 2000-03-17 2003-06-25 贝尼泰克澳大利亚有限公司 遗传沉默
EP1229134A3 (en) * 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
AU2004209579B2 (en) * 2003-02-10 2010-03-04 Lorus Therapeutics Inc. Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer
WO2004083432A1 (en) * 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP1636363A1 (en) * 2003-05-21 2006-03-22 GeneSense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CN1910293B (zh) 2003-10-23 2011-04-13 伊洛默格生物科学公司 检测与抗病毒感染性有关的基因oas1中的突变的方法
WO2005065719A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
EP1744761A4 (en) * 2004-04-28 2010-01-13 Molecules For Health Inc METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER
EP2322650A1 (en) * 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
EP1786905B1 (en) * 2004-08-18 2011-08-03 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
CA2603730A1 (en) * 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
WO2010027279A2 (en) * 2008-09-04 2010-03-11 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
EP2727996A1 (en) 2008-11-06 2014-05-07 The Johns-Hopkins University Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012052258A1 (en) * 2010-10-18 2012-04-26 Arrowhead Research Corporation Compositions and methods for inhibiting expression of rrm2 genes
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
KR20140090218A (ko) 2011-10-28 2014-07-16 노파르티스 아게 신규 퓨린 유도체 및 질환의 치료에서의 그의 용도
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
CA2930359C (en) 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
AU6490894A (en) * 1993-03-23 1994-10-11 Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BJORKLUND ET AL. BIOCHEM. 1990. 29(23):5452-8 *

Also Published As

Publication number Publication date
AU3617597A (en) 1998-02-25
CA2262776C (en) 2005-03-08
WO1998005769A3 (en) 1998-06-25
CN1231694A (zh) 1999-10-13
EP0917569A2 (en) 1999-05-26
NZ333802A (en) 2001-09-28
CA2262776A1 (en) 1998-02-12
CN1189562C (zh) 2005-02-16
WO1998005769A2 (en) 1998-02-12
ATE309345T1 (de) 2005-11-15
JP4301576B2 (ja) 2009-07-22
AU738592B2 (en) 2001-09-20
DE69734589T2 (de) 2006-08-10
ES2256893T3 (es) 2006-07-16
IL128124A (en) 2006-12-31
IL128124A0 (en) 1999-11-30
JP2000517167A (ja) 2000-12-26
DE69734589D1 (de) 2005-12-15
EP0917569B1 (en) 2005-11-09
US5998383A (en) 1999-12-07

Similar Documents

Publication Publication Date Title
AU738592C (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US7223849B1 (en) Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
EP0748383B1 (en) Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences
EP1153128B1 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
US7405205B2 (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
AU9732101A (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
EP0971731B1 (en) Suppression of malignancy utilizing ribonucleotide reductase r1
TW200823287A (en) Composition and method for treatment of tumors
Lee et al. Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin
HK1024640B (en) Suppression of malignancy utilizing ribonucleotide reductase r1

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT TO READ GENESENSE TECHNOLOGIES INC.

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20011220

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20020124